Greenwich Lifesciences, Inc. insider trading

Every open-market purchase and sale by Greenwich Lifesciences, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $586,328 13 trades by 1 insider 3 months later: median +27.4% (+23.6% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Greenwich Lifesciences, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Greenwich Lifesciences, Inc.’s insiders pay?

From November 20, 2020 to July 30, 2026, 4 insiders reported 83 open-market purchases and 0 sales not made under a pre-set plan in Greenwich Lifesciences, Inc. Twelve months after each purchase was reported, the shares were +10.0% against the S&P 500 on average (median −10.6%), over 72 purchases with a full year of prices; 36% beat the index. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 23, 2020 into $29,982 by November 2, 2026, +20.4% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $22,945 (+15.1% a year), and held throughout $22,945 (+15.1%).

Copying Greenwich Lifesciences, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Greenwich Lifesciences, Inc.'s insiders from November 23, 2020, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 100% of the time.

Greenwich Lifesciences, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Patel Snehal	CEO and CFO	73	+7.7% (62)	40%	—	July 30, 2026
Thompson Jaye	VP Clinical Reg Affairs	6	−31.0% (6)	0%	—	November 25, 2024
Daugherty Frank Joseph	Chief Medical Officer	3	−21.6% (3)	0%	—	April 26, 2022
Rothe Eric	Director	1	+496.2% (1)	100%	—	November 24, 2020

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Greenwich Lifesciences, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Greenwich Lifesciences, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 5 buying crowds with six months of prices, it averaged +104.6% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
January 31, 2025	2 buying	−17.3%	−13.2%	+100.7%
July 31, 2024	2 buying	−18.2%	−29.7%	−41.9%
April 28, 2023	2 buying	−24.6%	−19.9%	−6.5%
December 31, 2021	2 buying	−15.7%	−45.0%	−21.5%
November 30, 2020	2 buying	+403.8%	+631.0%	+465.4%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Greenwich Lifesciences, Inc. · Funds · Politicians